1. Home
  2. ADPT vs BSM Comparison

ADPT vs BSM Comparison

Compare ADPT & BSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$24.81

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Logo Black Stone Minerals L.P.

BSM

Black Stone Minerals L.P.

HOLD

Current Price

$14.07

Market Cap

3.0B

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADPT
BSM
Founded
2009
1876
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
3.0B
IPO Year
2019
2015

Fundamental Metrics

Financial Performance
Metric
ADPT
BSM
Price
$24.81
$14.07
Analyst Decision
Strong Buy
Hold
Analyst Count
9
1
Target Price
$17.78
$14.00
AVG Volume (30 Days)
2.7M
324.6K
Earning Date
05-05-2026
05-04-2026
Dividend Yield
N/A
8.40%
EPS Growth
63.89
N/A
EPS
N/A
N/A
Revenue
$276,976,000.00
$469,919,000.00
Revenue This Year
$3.98
$11.03
Revenue Next Year
$22.72
$9.63
P/E Ratio
N/A
$12.82
Revenue Growth
54.77
8.35
52 Week Low
$11.93
$11.90
52 Week High
$24.96
$15.49

Technical Indicators

Market Signals
Indicator
ADPT
BSM
Relative Strength Index (RSI) 58.80 43.95
Support Level $15.08 $13.46
Resistance Level N/A $14.45
Average True Range (ATR) 1.38 0.29
MACD -0.01 -0.04
Stochastic Oscillator 66.50 16.36

Price Performance

Historical Comparison
ADPT
BSM

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

About BSM Black Stone Minerals L.P.

Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests. The company owns mineral interests in approximately 16.9 million gross acres.

Share on Social Networks: